Table 1 Demographics, spirometry, and clinical characteristics of COPD subjects stratified by history of GERD*
From: Impact of self-reported Gastroesophageal reflux disease in subjects from COPDGene cohort
|  | GERD (n = 1,307) | No GERD (n=3,176) | Total (n=4,483) | P-value |
|---|---|---|---|---|
Age (years) [mean (s.d.)] | 63.9 (8.2) | 62.7 (8.8) | 63.1 (8.6) | <0.0001 |
Gender (% female) | 50.9 | 41.3 | 44.1 | <0.0001 |
FEV1% predicted [mean (s.d.)] | 56.3 (21.4) | 57.9 (23.3) | 57.4 (22.8) | 0.02 |
Spirometry Gold Stage (%) | Â | Â | Â | Â |
Stage 1-2 | 60.1 | 60.7 | 60.6 | Â |
Stage 3-4 | 39.9 | 39.3 | 39.4 | 0.67 |
Body mass index (kg/m2) [mean (s.d.)] | 28.8 (6.1) | 27.5 (6.1) | 27.9 (6.1) | <0.0001 |
Current smoking (% of each group) | 34.3 | 47.1 | 43.3 | <0.0001 |
Pack years [mean (s.d.)] | 53.4 (27.6) | 50.8 (27.0) | 51.6 (27.2) | 0.003 |
Currently works (% patients) | 24.4 | 28.0 | 26.9 | 0.01 |
Education beyond high school (% patients) | 60.9 | 59.7 | 60.1 | 0.45 |
Chronic bronchitis (% patients) | 29.0 | 24.7 | 25.9 | 0.002 |
Short-acting beta-agonists (% of patients) | 61.0 | 48.5 | 52.1 | <0.0001 |
Long-acting beta-agonists [LABA] (% of patients) | 9.1 | 6.5 | 7.3 | 0.011 |
Inhaled corticosteroids [ICS] (% of patients) | 13.9 | 9.3 | 10.6 | <0.0001 |
Combination ICS/LABA (% of patients) | 41.7 | 33.6 | 36.0 | <0.0001 |
Long acting anti-muscarinic (% of patients) | 40.2 | 30.8 | 33.5 | <0.0001 |
Any GERD therapy (% of patients) | 52.8 | 8.2 | 21.2 | <0.0001 |
Proton Pump Inhibitors (% of patients) | 46.8 | 6.5 | 18.2 | <0.0001 |